Your browser doesn't support javascript.
loading
Plasmablastic Lymphoma: Case Report of Prolonged Survival of an Advanced Human Immunodeficiency Patient and Literature Review.
Rafei, Hind; El-Bahesh, Ehab; Finianos, Antoine; Liu, Min-Ling L; Schechter, Geraldine P.
Afiliação
  • Rafei H; Division of Internal Medicine of the Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
  • El-Bahesh E; Division of Hematology Oncology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
  • Finianos A; Hematology Section, Medical Service, Veterans Affairs Medical Center, Washington, DC, USA.
  • Liu ML; Division of Hematology Oncology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
  • Schechter GP; Hematology Section, Medical Service, Veterans Affairs Medical Center, Washington, DC, USA.
Case Rep Hematol ; 2017: 9561013, 2017.
Article em En | MEDLINE | ID: mdl-29090101
ABSTRACT
Clinical Practice Points. Plasmablastic lymphoma (PBL) is a rare and highly aggressive variant of diffuse large B cell lymphoma with median survival of advanced stage patients varying between 6 and 15 months in previous reports. We report here a human immunodeficiency virus-infected patient surviving over 12 years following treatment for advanced PBL with EPOCH chemotherapy and intrathecal therapy. This case highlights the potential for improved survival in PBL with intensive chemotherapy. Further, literature review suggests promising prospects utilizing novel targeted therapies to increase the rate of prolonged responses.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Case Rep Hematol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Case Rep Hematol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos